Biogen presented Phase 2 CELIA study data on diranersen, an investigational antisense oligonucleotide therapy targeting tau protein, at the Alzheimer's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE